Last reviewed 2026-04-20 · How we verify

Chantix (Varenicline Tartrate)

Varenicline binds α4β2 neuronal nicotinic acetylcholine receptors as partial agonist, blocking nicotine binding and dopamine reward.

Varenicline is a nicotinic receptor partial agonist indicated as an aid to smoking cessation treatment. It demonstrates high selectivity for α4β2 neuronal nicotinic acetylcholine receptors with favorable pharmacokinetics including ~90% bioavailability, 24-hour half-life, and minimal hepatic metabolism. Primary risks include adverse events when combined with nicotine replacement therapy and potential drug interactions requiring dose adjustments for medications like warfarin and theophylline. Varenicline represents an effective pharmacological approach to smoking cessation with a well-characterized mechanism and manageable safety profile when used as monotherapy.

At a glance

Mechanism of action

Varenicline binds with high affinity and selectivity to α4β2 neuronal nicotinic acetylcholine receptors. Its efficacy in smoking cessation results from dual activity: it produces agonist activity at these receptors while simultaneously preventing nicotine binding. Electrophysiology and neurochemical studies demonstrate that varenicline stimulates receptor-mediated activity at significantly lower levels than nicotine. Varenicline blocks nicotine's ability to activate α4β2 receptors and stimulate the central nervous mesolimbic dopamine system, which is believed to underlie the reinforcement and reward experienced during smoking. This mechanism effectively reduces the addictive properties of nicotine. Varenicline demonstrates high selectivity for α4β2 receptors compared to other nicotinic receptors (>500-fold over α3β4, >3,500-fold over α7, >20,000-fold over α1βγδ) and non-nicotinic receptors and transporters (>2,000-fold). It also binds with moderate affinity to the 5-HT3 receptor.

Approved indications

• Treatment of adult smokers to help them stop smoking
• Treatment of adult smokers with a history of serious psychiatric illness to help them stop smoking

Boxed warnings

• WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric events including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide have been reported in patients taking CHANTIX. Some reported cases may have been complicated by the symptoms of nicotine withdrawal in patients who stopped smoking. Depressed mood may be a symptom of nicotine withdrawal. Depression, rarely including suicidal ideation, has been reported in smokers undergoing a smoking cessati

Common side effects

• Insomnia
• Nausea
• Skin Rash
• Changes in Mood
• Itching/Hives
• Headache

Drug interactions

• Transdermal nicotine (nicotine replacement therapy)
• Bupropion
• Theophylline, warfarin, insulin

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Chantix CI brief — competitive landscape report
• Chantix updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI